US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myeloma
The US Food and Drug Administration (FDA – the medicines regulator in the US) has granted approval to a “supplemental biologics license application” for teclistamab-cqvy (Tecvayli®). This means the existing FDA teclistamab license has been extended to…